KURA ONCOLOGY INC (KURA)
US50127T1097 - Common Stock
Overall KURA gets a fundamental rating of 2 out of 10. We evaluated KURA against 565 industry peers in the Biotechnology industry. The financial health of KURA is average, but there are quite some concerns on its profitability. KURA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
KURA had negative earnings in the past year.
KURA had a negative operating cash flow in the past year.
KURA had negative earnings in each of the past 5 years.
KURA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
KURA's Return On Assets of -41.26% is in line compared to the rest of the industry. KURA outperforms 56.05% of its industry peers.
The Return On Equity of KURA (-46.62%) is better than 68.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.26% | ||
| ROE | -46.62% | ||
| ROIC | N/A |
ROA(3y)-29.4%
ROA(5y)-25.63%
ROE(3y)-32.16%
ROE(5y)-28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, KURA has more shares outstanding
Compared to 5 years ago, KURA has more shares outstanding
Compared to 1 year ago, KURA has a worse debt to assets ratio.
2.2 Solvency
KURA has an Altman-Z score of 4.63. This indicates that KURA is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.63, KURA is doing good in the industry, outperforming 79.72% of the companies in the same industry.
KURA has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
KURA has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: KURA outperforms 42.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.63 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 11.47 indicates that KURA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.47, KURA belongs to the best of the industry, outperforming 84.70% of the companies in the same industry.
A Quick Ratio of 11.47 indicates that KURA has no problem at all paying its short term obligations.
KURA has a better Quick ratio (11.47) than 84.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.47 | ||
| Quick Ratio | 11.47 |
3. Growth
3.1 Past
KURA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.83%.
EPS 1Y (TTM)-16.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, KURA will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.5%
EPS Next 2Y-5.95%
EPS Next 3Y-3.23%
EPS Next 5Y13.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
KURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KURA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KURA's earnings are expected to decrease with -3.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.95%
EPS Next 3Y-3.23%
5. Dividend
5.1 Amount
KURA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KURA ONCOLOGY INC
NASDAQ:KURA (12/20/2024, 6:30:43 PM)
After market: 9.1738 +0.16 (+1.82%)9.01
+0.04 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.16%
Inst Owner Change0.29%
Ins Owners1.07%
Ins Owner Change-0.01%
Market Cap700.62M
Analysts83.64
Price Target29.14 (223.42%)
Short Float %9.73%
Short Ratio4.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.66%
Min EPS beat(2)1.27%
Max EPS beat(2)8.05%
EPS beat(4)3
Avg EPS beat(4)1.48%
Min EPS beat(4)-5.24%
Max EPS beat(4)8.05%
EPS beat(8)7
Avg EPS beat(8)6.01%
EPS beat(12)11
Avg EPS beat(12)6.1%
EPS beat(16)13
Avg EPS beat(16)4.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.23%
PT rev (3m)-6.07%
EPS NQ rev (1m)37.91%
EPS NQ rev (3m)42.93%
EPS NY rev (1m)15.42%
EPS NY rev (3m)15.04%
Revenue NQ rev (1m)1091.69%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.65 | ||
| P/tB | 1.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.36
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.17
OCFYN/A
SpS0
BVpS5.45
TBVpS5.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.26% | ||
| ROE | -46.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-29.4%
ROA(5y)-25.63%
ROE(3y)-32.16%
ROE(5y)-28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.83% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.47 | ||
| Quick Ratio | 11.47 | ||
| Altman-Z | 4.63 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)102.68%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26%
EPS Next Y-1.5%
EPS Next 2Y-5.95%
EPS Next 3Y-3.23%
EPS Next 5Y13.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.33%
EBIT Next 3Y-18.94%
EBIT Next 5Y-2.67%
FCF growth 1Y-57.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.22%
OCF growth 3YN/A
OCF growth 5YN/A